Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
Launched by YU BO · May 8, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is following up with patients who have survived an acute myocardial infarction, which is a serious heart event commonly known as a heart attack. The study aims to gather information about the long-term health and medication use of these patients. It specifically looks at important health events that may occur after the heart attack, such as additional heart problems, strokes, or even death. The researchers are reaching out to patients by phone three years and five years after they were discharged from the hospital to collect this information.
To participate in this trial, you need to have been part of a previous study focusing on heart protection and completed a health check one year after your heart attack. The trial is open to all adults aged 65 and older who meet these criteria. If you choose to take part, you can expect a phone call from the research team to discuss your current health and any heart-related issues you've experienced since your initial treatment. This follow-up is important to help doctors understand how survivors of heart attacks are doing over time and to improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • AMI survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" and completed the 1-year visit.
- • Telephone to obtain informed consent from the subjects/family members of the subjects.
- Exclusion Criteria:
- • Not available
About Yu Bo
Yu Bo is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to improving patient outcomes, Yu Bo specializes in the development and management of clinical studies across various therapeutic areas. The organization emphasizes rigorous scientific methodologies and regulatory compliance, ensuring the highest standards of quality and safety in all trials. By fostering collaboration with healthcare professionals and research institutions, Yu Bo aims to accelerate the discovery of novel treatments and contribute to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Guangzhou, Guangdong, China
Zhengzhou, Henan, China
Nanning, Guangxi, China
Nanchang, Jiangxi, China
Nanjing, Jiangsu, China
Daqing, Heilongjiang, China
Beijing, Beijing, China
Tianjin, Tianjin, China
Beijing, Beijing, China
Beijing, Beijing, China
Tianjing, Tianjin, China
ürümqi, Xinjiang, China
Shijiazhuang, Hebei, China
Chongqing, Sichuan, China
Changchun, Jilin, China
Dalian, Liaoning, China
Shenyang, Liaoning, China
Xi'an, Shanxi, China
Patients applied
Trial Officials
Bo Yu
Study Chair
The Second Affiliated Hospital of Harbin Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported